Top Markets
#1 Black Phoenix Black Phoenix +342.75%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +61.75%
#4 Gold Park Gold Park +55.15%
#5 BasedHype BasedHype +29.66%
#6 Acurast Acurast +25.65%
#7 Cryptopia Cryptopia +22.04%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.03%
#9 Avantis Avantis +18.81%
#10 MYX Finance MYX Finance +14.22%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Rangering i aksjer #40868
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Aksjekurs
$0.02765
Sist synkronisert: 2024-12-23
Markedsverdi
$69.04K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Histogen Inc. (HSTO)

Kategori

Healthcare
Inntekter for Histogen Inc. (HSTO)
Inntekter i Sep 2023 TTM: $-12.38M
Ifølge Histogen Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $-12.38M. I 2021 hadde selskapet et resultat på $-15.01M, en økning sammenlignet med resultatet i 2020, som var $-18.82M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Histogen Inc. fra 2011 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-12.38M 16.35%
2022 $-10.64M -29.08%
2021 $-15.01M -20.24%
2020 $-18.82M 65.28%
2019 $-11.39M -36.79%
2018 $-18.01M 3.53%
2017 $-17.40M -41.49%
2016 $-29.73M 23.12%
2015 $-24.15M 8.19%
2014 $-22.32M 42.93%
2013 $-15.62M 78.48%
2012 $-8.75M -27.07%
2011 $-12.00M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -42,694.48%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -15,851.37%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -24,370.97%
BE